Skip to content

Author

Daniel Weiss

We have 2 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Real-world experience with foslevodopa/foscarbidopa in Germany: therapeutic insights and lessons learned

Patients with advanced Parkinson’s disease (PD) often need to continue with device-aided therapies (DAT), such as intestinal and subcutaneous infusion therapies. Recently, continuous subcutaneous administration of foslevodopa/foscarbidopa (LDp/CDp) has emerged as a new therapeutic method. Two years after its approval i...

D. Weise, Tobias Warnecke, Carsten Buhmann et al. · 0 citations
Open access Oct 2026

Disease Duration Differentiates Freezing of Gait Response to Subthalamic and Nigral Stimulation for Parkinson's Disease in an Exploratory Multicenter Controlled Trial

Abstract Background Freezing of gait (FoG) belongs to most pressing unmet symptoms in the treatment of Parkinson's disease. Objectives To explore whether combined subthalamic and nigral (STN + SNr) deep brain stimulation improves FoG compared with optimized STN stimulation alone; to identify clinical variables associat...

Daniel Weiss, I. Cebi, Marion Schütt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.